Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease

PLoS ONE - Tập 10 Số 8 - Trang e0134172
Hongmei Yan1, Mingfeng Xia1, Yan Wang2, Xin Gao1, Lisheng Wang3, Shengxiang Rao3, Mengsu Zeng3, Yinfang Tu4, Ru Feng2, Weiping Jia4, Jun Liu5, Wei Deng6, Jian‐Dong Jiang2
1Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China
3Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4Department of Endocrinology and Metabolism, The Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, 200233, China
5Department of Endocrinology and Metabolism, The Fifth People’s Hospital, Fudan University, Shanghai, 200240, China
6School of Public Health, Fudan University, Shanghai 200032, China

Tóm tắt

Từ khóa


Tài liệu tham khảo

NM de Alwis, 2008, Non-alcoholic fatty liver disease: the mist gradually clears, J Hepatol, 48, S104, 10.1016/j.jhep.2008.01.009

GC Farrell, 2006, Nonalcoholic fatty liver disease: from steatosis to cirrhosis, Hepatology, 43, S99, 10.1002/hep.20973

QM Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, 330, 10.1038/nrgastro.2013.41

LA Adams, 2009, NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study, Am J Gastroenterol, 104, 861, 10.1038/ajg.2009.67

R Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326

AJ Sanyal, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929

GP Aithal, 2008, Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis, Gastroenterology, 135, 1176, 10.1053/j.gastro.2008.06.047

J Yin, 2008, Efficacy of berberine in patients with type 2 diabetes mellitus, Metabolism, 57, 712, 10.1016/j.metabol.2008.01.013

W Kong, 2004, Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins, Nat Med, 10, 1344, 10.1038/nm1135

J Cameron, 2008, Berberine decreases PCSK9 expression in HepG2 cells, Atherosclerosis, 201, 266, 10.1016/j.atherosclerosis.2008.02.004

SS Lu, 2009, Berberine promotes glucagon-like peptide-1 (7–36) amide secretion in streptozotocin-induced diabetic rats, Journal of Endocrinology, 200, 159

WJ Kong, 2009, Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression, Metabolism: Clinical and Experimental, 58, 109, 10.1016/j.metabol.2008.08.013

Y Zhang, 2008, Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine, J Clin Endocrinol Metab, 93, 2559, 10.1210/jc.2007-2404

RJ Perry, 2014, The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes, Nature, 510, 84, 10.1038/nature13478

X Chang, 2010, Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats, J Lipid Rese, 51, 2504, 10.1194/jlr.M001958

LS Szczepaniak, 2005, Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population, Am J Physiol Endocrinol Metab, 288, E462, 10.1152/ajpendo.00064.2004

GC Farrell, 2007, Guidelines for the assessment and management of nonalcoholic fatty liver disease in the Asia-Pacific region: executive summary, J Gastroenterol Hepatol, 22, 775, 10.1111/j.1440-1746.2007.05002.x

E. Cho, 1990, Berberini hydrochloride, in Pharmacopoeia of the People’s Republic of China, 2, 437

A Astrup, 2012, Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide, Int J Obes (Lond), 36, 843, 10.1038/ijo.2011.158

XS Tan, 2013, Tissue distribution of berberine and its metabolites after oral administration in rats, PLoS One, 8, e77969, 10.1371/journal.pone.0077969

H Bian, 2011, Increased liver fat content and unfavorable glucose profiles in subjects without diabetes, Diabetes Technol. Ther, 13, 149, 10.1089/dia.2010.0101

JY Ma, 2013, Excretion of berberine and its metabolites in oral administration in rats, J Pharm Sci, 102, 4181, 10.1002/jps.23718

R Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326

M Takihata, 2013, Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial, Diabetes Obes Metab, 15, 455, 10.1111/dom.12055

W Chen, 2011, Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats, Aaps Pharmscitech, 12, 705, 10.1208/s12249-011-9632-z

W Hua, 2007, Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry, J Pharm Biomed Anal, 44, 931, 10.1016/j.jpba.2007.03.022

W Xie, 2011, Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice, PLoS One, 6, e24520, 10.1371/journal.pone.0024520

YT Liu, 2010, Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats, Drug Metab Dispos, 38, 1779, 10.1124/dmd.110.033936

J Liu, 2011, Tissue distribution of 4 alkaloids of Compound Matrine Injection in rats, Pharmacology and Clinics of Chinese Materia Medica, 27, 74

K Lee, 2011, Mitochondrial carnitine palmitoyltransferase 1a (CPT1a) is part of an outer membrane fatty acid transfer complex, J Biol Chem, 286, 25655, 10.1074/jbc.M111.228692

E Reiling, 2009, Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk, Diabetologia, 52, 1866, 10.1007/s00125-009-1413-9

YS Lee, 2006, Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states, Diabetes, 55, 2256, 10.2337/db06-0006

H Li, 2014, Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK, Cardiovasc Diabetol, 13, 24, 10.1186/1475-2840-13-24